Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J5FU
|
||||
| Former ID |
DCL000168
|
||||
| Drug Name |
MIV-701
|
||||
| Indication | Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] | Discontinued in Phase 1 | [1] | ||
| Company |
Medivir
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Lysosome | ||||
| Osteoclast differentiation | |||||
| Toll-like receptor signaling pathway | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016480) | ||||
| REF 2 | Medivir designates MIV-710 a Candidate Drug (CD) for Osteoporosis and Osteoarthritis, 2009 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.